218 related articles for article (PubMed ID: 34445387)
1. Syndecan Family Gene and Protein Expression and Their Prognostic Values for Prostate Cancer.
Santos NJ; Barquilha CN; Barbosa IC; Macedo RT; Lima FO; Justulin LA; Barbosa GO; Carvalho HF; Felisbino SL
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445387
[TBL] [Abstract][Full Text] [Related]
2. Random forest-based modelling to detect biomarkers for prostate cancer progression.
Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
[TBL] [Abstract][Full Text] [Related]
3. Soluble syndecan-1 (SDC1) serum level as an independent pre-operative predictor of cancer-specific survival in prostate cancer.
Szarvas T; Reis H; Vom Dorp F; Tschirdewahn S; Niedworok C; Nyirady P; Schmid KW; Rübben H; Kovalszky I
Prostate; 2016 Aug; 76(11):977-85. PubMed ID: 27062540
[TBL] [Abstract][Full Text] [Related]
4. Sulfiredoxin as a Potential Therapeutic Target for Advanced and Metastatic Prostate Cancer.
Barquilha CN; Santos NJ; Monção CCD; Barbosa IC; Lima FO; Justulin LA; Pértega-Gomes N; Felisbino SL
Oxid Med Cell Longev; 2020; 2020():2148562. PubMed ID: 32411320
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel cell glycolysis related gene signature predicting survival in patients with breast cancer.
Jiang F; Wu C; Wang M; Wei K; Wang J
Sci Rep; 2021 Feb; 11(1):3986. PubMed ID: 33597614
[TBL] [Abstract][Full Text] [Related]
6. A subset of high Gleason grade prostate carcinomas contain a large burden of prostate cancer syndecan-1 positive stromal cells.
Sharpe B; Alghezi DA; Cattermole C; Beresford M; Bowen R; Mitchard J; Chalmers AD
Prostate; 2017 May; 77(13):1312-1324. PubMed ID: 28744948
[TBL] [Abstract][Full Text] [Related]
7. FASN Protein Overexpression Indicates Poor Biochemical Recurrence-Free Survival in Prostate Cancer.
Cao Z; Xu Y; Guo F; Chen X; Ji J; Xu H; He J; Yu Y; Sun Y; Lu X; Wang F
Dis Markers; 2020; 2020():3904947. PubMed ID: 32655718
[TBL] [Abstract][Full Text] [Related]
8. Altered expression patterns of syndecan-1 and -2 predict biochemical recurrence in prostate cancer.
Ledezma R; Cifuentes F; Gallegos I; Fullá J; Ossandon E; Castellon EA; Contreras HR
Asian J Androl; 2011 May; 13(3):476-80. PubMed ID: 21317913
[TBL] [Abstract][Full Text] [Related]
9. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer.
Zellweger T; Ninck C; Mirlacher M; Annefeld M; Glass AG; Gasser TC; Mihatsch MJ; Gelmann EP; Bubendorf L
Prostate; 2003 Apr; 55(1):20-9. PubMed ID: 12640657
[TBL] [Abstract][Full Text] [Related]
10. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
11. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
[TBL] [Abstract][Full Text] [Related]
12. Association of heparan sulfate proteoglycans SDC1 and SDC4 polymorphisms with breast cancer in an Australian Caucasian population.
Okolicsanyi RK; Buffiere A; Jacinto JM; Chacon-Cortes D; Chambers SK; Youl PH; Haupt LM; Griffiths LR
Tumour Biol; 2015 Mar; 36(3):1731-8. PubMed ID: 25361632
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and clinical significance of syndecan-1 expression in breast cancer: A systematic review and meta-analysis.
Qiao W; Liu H; Guo W; Li P; Deng M
Eur J Surg Oncol; 2019 Jul; 45(7):1132-1137. PubMed ID: 30598194
[TBL] [Abstract][Full Text] [Related]
15. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
16. Two novel predictive biomarkers for osteosarcoma and glycolysis pathways: A profiling study on HS2ST1 and SDC3.
Yang G; Jiang J; Yin R; Li Z; Li L; Gao F; Liu C; Zhan X
Medicine (Baltimore); 2022 Sep; 101(36):e30192. PubMed ID: 36086752
[TBL] [Abstract][Full Text] [Related]
17. CircRNA SCARB1 Promotes Renal Cell Carcinoma Progression Via Mir- 510-5p/SDC3 Axis.
Sun J; Pan S; Cui H; Li H
Curr Cancer Drug Targets; 2020; 20(6):461-470. PubMed ID: 32271695
[TBL] [Abstract][Full Text] [Related]
18. Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine.
Akl MR; Nagpal P; Ayoub NM; Prabhu SA; Gliksman M; Tai B; Hatipoglu A; Goy A; Suh KS
Oncotarget; 2015 Oct; 6(30):28693-715. PubMed ID: 26293675
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients.
Gharbaran R; Goy A; Tanaka T; Park J; Kim C; Hasan N; Vemulapalli S; Sarojini S; Tuluc M; Nalley K; Bhattacharyya P; Pecora A; Suh KS
J Hematol Oncol; 2013 Aug; 6():62. PubMed ID: 23988031
[TBL] [Abstract][Full Text] [Related]
20. Expression of heparan sulfate proteoglycans in murine models of experimental colitis.
Patterson AM; Delday MI; van Kuppevelt TH; Loh G; Blaut M; Haller D; Grant G; Kelly D
Inflamm Bowel Dis; 2012 Jun; 18(6):1112-26. PubMed ID: 21987406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
